Literature DB >> 17116821

Surgical resection of cutaneous head and neck lesions: does aspirin use increase hemorrhagic risk?

Muthuswamy Dhiwakar1, Najib A Khan, Leo G McClymont.   

Abstract

OBJECTIVE: To determine whether the antiplatelet agent aspirin increases hemorrhagic risk in patients undergoing surgical resection of cutaneous head and neck lesions.
DESIGN: Retrospective cohort study.
SETTING: Regional referral center. Patients All cases of cutaneous head and neck lesions surgically resected during a 10-year period were included. MAIN OUTCOME MEASURES: Outcome measures were incidence of significant postoperative hemorrhage, defined as postoperative hematoma or hemorrhage necessitating surgical reexploration; and total postoperative hemorrhage, defined as any hemorrhage lasting longer than 4 hours despite external pressure, requiring medical review, and resulting in prolongation of the patient's hospital stay or readmission to the hospital.
RESULTS: Seven hundred eleven patients (974 cases) were eligible for inclusion, of whom 320 were receiving aspirin therapy at the time of surgery. The incidence of significant postoperative hemorrhage in the aspirin and nonaspirin groups was 5 (1.6%) and 0, respectively (P = .004), and aspirin use was the only risk factor for significant postoperative hemorrhage. The incidence of total postoperative hemorrhage in the aspirin and nonaspirin groups was 7 (2.2%) and 1 (0.1%), respectively (P = .002). At multivariate analysis, aspirin use and local flap reconstruction were independent risk factors for total postoperative hemorrhage. Cases receiving aspirin therapy who also underwent local flap reconstruction were at exponential (124-fold) increased risk of total postoperative hemorrhage compared with cases with neither risk factor.
CONCLUSIONS: Aspirin intake at the time of surgery to resect cutaneous head and neck lesions confers a small but statistically increased risk of postoperative hemorrhage. This risk is particularly pronounced in patients undergoing local flap reconstruction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116821     DOI: 10.1001/archotol.132.11.1237

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  7 in total

1.  The effect of aspirin on bleeding after extraction of teeth.

Authors:  Nasser Nooh
Journal:  Saudi Dent J       Date:  2009-08-05

2.  Acute bleeding in the head and neck: angiographic findings and endovascular management.

Authors:  L-B Zhao; H B Shi; S Park; D G Lee; J H Shim; D H Lee; D C Suh
Journal:  AJNR Am J Neuroradiol       Date:  2013-10-17       Impact factor: 3.825

3.  Through-and-Through Mattress Suturing Versus Tie-Over Dressing in Full-Thickness Skin Graft Reconstruction.

Authors:  Siew Min Keh; Neil Giblett; Syed Farhan Ahsan
Journal:  Turk Arch Otorhinolaryngol       Date:  2017-08-16

4.  Association of Continued Preoperative Aspirin Use and Bleeding Complications in Patients Undergoing Thyroid Surgery.

Authors:  Blake S Raggio; Blair M Barton; Emad Kandil; Paul L Friedlander
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-04-01       Impact factor: 6.223

5.  Effect of heparin on prevention of flap loss in microsurgical free flap transfer: a meta-analysis.

Authors:  Xuan-Liang Pan; Guo-Xian Chen; Hua-Wei Shao; Chun-Mao Han; Li-Ping Zhang; Li-Zhu Zhi
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

6.  Hemorrhagic complications of cutaneous surgery for patients taking antithrombotic therapy: a systematic review and meta-analysis.

Authors:  George F Bonadurer; Andrea P Langeveld; Soogan C Lalla; Randall K Roenigk; Christopher J Arpey; Clark C Otley; Christian L Baum; Leah C Osterhaus Trzasko; Jerry D Brewer
Journal:  Arch Dermatol Res       Date:  2021-06-16       Impact factor: 3.017

7.  Aspirin use and bleeding volume in skin cancer patients undergoing surgery: a randomized controlled trial.

Authors:  Arman Engheta; Shahryar Hadadi Abianeh; Ali Atri; Mehdi Sanatkarfar
Journal:  Daru       Date:  2016-07-28       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.